Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays
NCT ID: NCT04023929
Last Updated: 2021-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
45 participants
OBSERVATIONAL
2020-10-28
2021-09-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Serosurveillance Study of Maternally Derived Anti-GBS Antibody
NCT04549220
Development of a Serocorrelate of Protection Against Invasive Group B Streptococcus Disease
NCT04735419
Group B Streptococcus: Attitudes to Immunisation in Pregnancy
NCT01982084
Pilot Study Freeze and Transport Immune Cells
NCT00138268
Developing a Controlled Human Infection Model for Group B Streptococcus (CHIM_GBS)
NCT04059510
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, is a devastating illness with a case fatality rate of 10-20% even with intensive treatment. Even infants who survive IMD experience significant disability in 10-20% of cases. Serogroups A, B, C, Y, W and X cause almost all cases of IMD, and in Europe, North America and parts of Latin America serogroup B is responsible for the majority of cases. In the UK there were 747 cases of IMD in 2016/17 and Men B was responsible for 396 (53%) of these. The major burden of disease is in infants under the age of 1 year. Pertussis is a highly infectious respiratory illness caused by Bordetella pertussis which can cause significant morbidity and mortality in young infants. There has been an increase in the incidence of pertussis in the UK, along with other high income countries in recent years which has disproportionately affected young infants.
Infants in the UK are vaccinated against meningococcal group B disease at 2, 4 and 12 months with Bexsero® and against pertussis at 2,3 and 4 months as part of the 6-in-1 vaccine Infanrix hexa®. Additionally, since 2012 pregnant women in the UK have been routinely offered pertussis vaccination during pregnancy to protect the infant in the first few months of life prior to them receiving their own vaccinations.
Serum bactericidal antibody (SBA) assays are important in the assessment of immunity following vaccination and are used in the production, release and licensure of some vaccines and the evaluation of the function of others. SBA assays for pertussis and meningococcal B typically use adult complement from a healthy adult donor pool. There is some concern that using adult complement may not allow an adequate assessment of neonatal immunity. The concentration of most complement components in the neonate is around 10-80% of that in the adult and circulating regulator levels are also reduced. Differences in complement function are more pronounced in preterm infants and the differences in the quality and activation of complement in neonates raises questions about whether an SBA assay using adult complement sources allows an accurate assessment of neonatal immunity.
In this study the investigators will create a pooled complement source for three different gestational ages, ≥37 gestational weeks, 32-36+6 gestational weeks and less than 32 gestational weeks, which will allow the investigators to compare the results of the pertussis and meningococcal SBA assays when using both standard adult complement and a gestational age appropriate complement source. To do this the investigators will collect cord blood samples from deliveries within the three gestational age groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Term babies
Babies who are born at or after 37 gestational weeks.
Cord blood sampling
A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
Preterm babies
Babies who are born between 32 and 36+6 gestational weeks.
Cord blood sampling
A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
Very preterm babies
Babies who are born before 32 gestational weeks.
Cord blood sampling
A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cord blood sampling
A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Known complement deficiency
16 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St George's, University of London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna Calvert, MBChB
Role: PRINCIPAL_INVESTIGATOR
St George's, Univeristy of London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St George's, University of London
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019.0116
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.